Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample

Heather Spencer Feigelson, Chan Zeng, Pamala A. Pawloski, Adedayo A. Onitilo, C. Sue Richards, Monique A. Johnson, Tia L. Kauffman, Jennifer Webster, Carsie Nyirenda, Gwen L. Alexander, Clara Hwang, Deanna Cross, Catherine A. McCarty, Robert Davis, Denise Schwarzkopf, Andrew E. Williams, Stacey Honda, Yihe Daida, Lawrence H. Kushi, Thomas Delate & 1 others Katrina A.B. Goddard

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Membership of the CERGEN Study Team is provided in the Acknowledgments. The Comparative Effectiveness Research in Genomics of Colon Cancer (CERGEN) Study Team includes: Gwen Alexander, Henry Ford Health System (HFHS); Chris Anderson, Health Partners Institute for Education and Research (HPIER); Ajay Behl, HPIER; Kris Bennett, Kaiser Permanente Northwest (KPNW); Kathleen Bow, Kaiser Permanente Hawai'i (KPHI); Jennifer Carney, KPHI; Ned Colange, Denver Public Health of Colorado; Christopher Cold, Marshfield Clinic Research Foundation (MCRF); Deanna Cross, MCRF; YeeHwa Daida, KPHI; Padmavati Dandamudi, KPNW; Robert Davis, KPG; Teri Defor, HPIER; Thomas Delate, Kaiser Permanente Colorado (KPCO); Jessica Engel, MCRF; Rene Faryniarz, HFHS; Heather Spencer Feigelson, KPCO (lead author); Thomas Flottemesch, HPIER; Mamie Ford, KPNC; Jared Freml, KPCO; Kellyan Funk, KPCO; Joan Garhy, HFHS; Katrina Goddard, KPNW; Julie Harris, Kaiser Permanente Northern California (KPNC); Mia Hemmes, Kaiser Permanente Georgia (KPG); Paul Hitz, MCRF; Rebecca Holmes, KPNW; Stacey Honda, KPHI; Stephen Houston, KPNW; Karl Huang, KPNC; Clara Hwang, HFHS; Sheng-Fang Jiang, KPNC; Monique Johnson, Oregon Health and Sciences University (OHSU); Tia Kauffman, KPNW; Terrie Kitchner, MCRF; Richard Krajenta HFHS; Tatjana Kolevska, KPNC; Lawrence Kushi, KPNC; Smyth Lai, KPNW; Anh Q Le, KPCO; Loic LeMarchand, University of Hawaii; Petra Liljestrand, KPNC;Jennifer Lin KPNW; Celeste Machen, KPNW; Michael Maciosek, HPIER; Catherine McCarty, MCRF; Jennifer McCance, KPCO; Richard Meenan, KPNW; Alex Menter, KPCO; Jill Mesa,KPNW; Paul Meier, HFHS; Anousheh Mirabedi, KPNC; Judith Morse, KPNC; Kristin Muessig,KPNW; Andrew Nelson, HPIER; Carsie Nyirenda, KPCO; Maureen O'Keeffe Rosetti, KPNW; Kim Olson, KPNW; Suzanne O'Neill, Georgetown University; Adedayo Onitilo, MCRF; Brian Owens, HPIER;Pamala Pawloski, HPIER; Alanna Rahm, KPCO; C. Sue Richards, OHSU; Denise Schwarzkopf, KPNW; Caitlin Senger, KPNW; Carol Somkin KPNC; Amy Stone-Murai, KPHI;Nagendra Tirumali, KPNW; Laurie VanArman, HPIER; David Veenstra, University of Washington; Aleli Vinoya, KPHI; Carmel Wax, KPNW; Elizabeth Webber, KPNW; Jennifer Webster, KPNW; Evelyn Whitlock KPNW; Andrew Williams, KPHI; Carmen Wong, KPHI; Chan Zeng, KPCO; Sarah Zuber, KPNW. Purpose: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. Patients and Methods: We included 1186 metastatic CRC cases from seven health plans. A cutpoint of July, 2008, was used to define two KRAS testing time period groups: "pre-testing" (n = 760 cases) and ''post-testing'' (n = 426 cases). Overall survival (OS) was estimated, and the difference in median OS between the groups was calculated. The lower bound of the one-sided 95% confidence interval (CI) for the difference in survival was used to test the null hypothesis of post-testing inferiority. Multivariable Cox regression models were constructed to adjust for covariates. Results: The median unadjusted OS was 15.4 months (95% CI: 14.0-17.5) and 12.8 months (95% CI: 10.0-15.2) in the pre-and post-testing groups, respectively. The OS difference was -2.6 months with one-sided 95% lower confidence bound of -5.13 months, which was less than the non-inferiority margin (-5.0 months, unadjusted p = 0.06), leading to a failure to reject inferiority of OS in the post-testing period. In contrast, in the adjusted analysis, OS non-inferiority was identified in the post-testing period (p = 0.001). Sensitivity analyses using cutpoints before and after July, 2008, also met the criteria for non-inferiority. Conclusion: Implementation of KRAS testing did not influence CRC OS. Our data support the use of KRAS testing to guide administration of EGFR inhibitors for treatment of metastatic CRC without diminished OS.

Original languageEnglish (US)
Article numbere94977
JournalPLoS ONE
Volume9
Issue number5
DOIs
StatePublished - May 1 2014

Fingerprint

colorectal neoplasms
Colorectal Neoplasms
Health
Testing
Population
education
Education
testing
sampling
Survival
Research
Comparative Effectiveness Research
confidence interval
Confidence Intervals
Genomics
Epidermal Growth Factor Receptor
Colonic Neoplasms
genomics
Waxes
Public health

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Feigelson, H. S., Zeng, C., Pawloski, P. A., Onitilo, A. A., Richards, C. S., Johnson, M. A., ... Goddard, K. A. B. (2014). Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. PLoS ONE, 9(5), [e94977]. https://doi.org/10.1371/journal.pone.0094977

Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. / Feigelson, Heather Spencer; Zeng, Chan; Pawloski, Pamala A.; Onitilo, Adedayo A.; Richards, C. Sue; Johnson, Monique A.; Kauffman, Tia L.; Webster, Jennifer; Nyirenda, Carsie; Alexander, Gwen L.; Hwang, Clara; Cross, Deanna; McCarty, Catherine A.; Davis, Robert; Schwarzkopf, Denise; Williams, Andrew E.; Honda, Stacey; Daida, Yihe; Kushi, Lawrence H.; Delate, Thomas; Goddard, Katrina A.B.

In: PLoS ONE, Vol. 9, No. 5, e94977, 01.05.2014.

Research output: Contribution to journalArticle

Feigelson, HS, Zeng, C, Pawloski, PA, Onitilo, AA, Richards, CS, Johnson, MA, Kauffman, TL, Webster, J, Nyirenda, C, Alexander, GL, Hwang, C, Cross, D, McCarty, CA, Davis, R, Schwarzkopf, D, Williams, AE, Honda, S, Daida, Y, Kushi, LH, Delate, T & Goddard, KAB 2014, 'Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample', PLoS ONE, vol. 9, no. 5, e94977. https://doi.org/10.1371/journal.pone.0094977
Feigelson, Heather Spencer ; Zeng, Chan ; Pawloski, Pamala A. ; Onitilo, Adedayo A. ; Richards, C. Sue ; Johnson, Monique A. ; Kauffman, Tia L. ; Webster, Jennifer ; Nyirenda, Carsie ; Alexander, Gwen L. ; Hwang, Clara ; Cross, Deanna ; McCarty, Catherine A. ; Davis, Robert ; Schwarzkopf, Denise ; Williams, Andrew E. ; Honda, Stacey ; Daida, Yihe ; Kushi, Lawrence H. ; Delate, Thomas ; Goddard, Katrina A.B. / Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample. In: PLoS ONE. 2014 ; Vol. 9, No. 5.
@article{73fd10d61c6e4b9b993b9a3e9badd918,
title = "Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample",
abstract = "Membership of the CERGEN Study Team is provided in the Acknowledgments. The Comparative Effectiveness Research in Genomics of Colon Cancer (CERGEN) Study Team includes: Gwen Alexander, Henry Ford Health System (HFHS); Chris Anderson, Health Partners Institute for Education and Research (HPIER); Ajay Behl, HPIER; Kris Bennett, Kaiser Permanente Northwest (KPNW); Kathleen Bow, Kaiser Permanente Hawai'i (KPHI); Jennifer Carney, KPHI; Ned Colange, Denver Public Health of Colorado; Christopher Cold, Marshfield Clinic Research Foundation (MCRF); Deanna Cross, MCRF; YeeHwa Daida, KPHI; Padmavati Dandamudi, KPNW; Robert Davis, KPG; Teri Defor, HPIER; Thomas Delate, Kaiser Permanente Colorado (KPCO); Jessica Engel, MCRF; Rene Faryniarz, HFHS; Heather Spencer Feigelson, KPCO (lead author); Thomas Flottemesch, HPIER; Mamie Ford, KPNC; Jared Freml, KPCO; Kellyan Funk, KPCO; Joan Garhy, HFHS; Katrina Goddard, KPNW; Julie Harris, Kaiser Permanente Northern California (KPNC); Mia Hemmes, Kaiser Permanente Georgia (KPG); Paul Hitz, MCRF; Rebecca Holmes, KPNW; Stacey Honda, KPHI; Stephen Houston, KPNW; Karl Huang, KPNC; Clara Hwang, HFHS; Sheng-Fang Jiang, KPNC; Monique Johnson, Oregon Health and Sciences University (OHSU); Tia Kauffman, KPNW; Terrie Kitchner, MCRF; Richard Krajenta HFHS; Tatjana Kolevska, KPNC; Lawrence Kushi, KPNC; Smyth Lai, KPNW; Anh Q Le, KPCO; Loic LeMarchand, University of Hawaii; Petra Liljestrand, KPNC;Jennifer Lin KPNW; Celeste Machen, KPNW; Michael Maciosek, HPIER; Catherine McCarty, MCRF; Jennifer McCance, KPCO; Richard Meenan, KPNW; Alex Menter, KPCO; Jill Mesa,KPNW; Paul Meier, HFHS; Anousheh Mirabedi, KPNC; Judith Morse, KPNC; Kristin Muessig,KPNW; Andrew Nelson, HPIER; Carsie Nyirenda, KPCO; Maureen O'Keeffe Rosetti, KPNW; Kim Olson, KPNW; Suzanne O'Neill, Georgetown University; Adedayo Onitilo, MCRF; Brian Owens, HPIER;Pamala Pawloski, HPIER; Alanna Rahm, KPCO; C. Sue Richards, OHSU; Denise Schwarzkopf, KPNW; Caitlin Senger, KPNW; Carol Somkin KPNC; Amy Stone-Murai, KPHI;Nagendra Tirumali, KPNW; Laurie VanArman, HPIER; David Veenstra, University of Washington; Aleli Vinoya, KPHI; Carmel Wax, KPNW; Elizabeth Webber, KPNW; Jennifer Webster, KPNW; Evelyn Whitlock KPNW; Andrew Williams, KPHI; Carmen Wong, KPHI; Chan Zeng, KPCO; Sarah Zuber, KPNW. Purpose: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. Patients and Methods: We included 1186 metastatic CRC cases from seven health plans. A cutpoint of July, 2008, was used to define two KRAS testing time period groups: {"}pre-testing{"} (n = 760 cases) and ''post-testing'' (n = 426 cases). Overall survival (OS) was estimated, and the difference in median OS between the groups was calculated. The lower bound of the one-sided 95{\%} confidence interval (CI) for the difference in survival was used to test the null hypothesis of post-testing inferiority. Multivariable Cox regression models were constructed to adjust for covariates. Results: The median unadjusted OS was 15.4 months (95{\%} CI: 14.0-17.5) and 12.8 months (95{\%} CI: 10.0-15.2) in the pre-and post-testing groups, respectively. The OS difference was -2.6 months with one-sided 95{\%} lower confidence bound of -5.13 months, which was less than the non-inferiority margin (-5.0 months, unadjusted p = 0.06), leading to a failure to reject inferiority of OS in the post-testing period. In contrast, in the adjusted analysis, OS non-inferiority was identified in the post-testing period (p = 0.001). Sensitivity analyses using cutpoints before and after July, 2008, also met the criteria for non-inferiority. Conclusion: Implementation of KRAS testing did not influence CRC OS. Our data support the use of KRAS testing to guide administration of EGFR inhibitors for treatment of metastatic CRC without diminished OS.",
author = "Feigelson, {Heather Spencer} and Chan Zeng and Pawloski, {Pamala A.} and Onitilo, {Adedayo A.} and Richards, {C. Sue} and Johnson, {Monique A.} and Kauffman, {Tia L.} and Jennifer Webster and Carsie Nyirenda and Alexander, {Gwen L.} and Clara Hwang and Deanna Cross and McCarty, {Catherine A.} and Robert Davis and Denise Schwarzkopf and Williams, {Andrew E.} and Stacey Honda and Yihe Daida and Kushi, {Lawrence H.} and Thomas Delate and Goddard, {Katrina A.B.}",
year = "2014",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0094977",
language = "English (US)",
volume = "9",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Does KRAS testing in metastatic colorectal cancer impact overall survival? A comparative effectiveness study in a population-based sample

AU - Feigelson, Heather Spencer

AU - Zeng, Chan

AU - Pawloski, Pamala A.

AU - Onitilo, Adedayo A.

AU - Richards, C. Sue

AU - Johnson, Monique A.

AU - Kauffman, Tia L.

AU - Webster, Jennifer

AU - Nyirenda, Carsie

AU - Alexander, Gwen L.

AU - Hwang, Clara

AU - Cross, Deanna

AU - McCarty, Catherine A.

AU - Davis, Robert

AU - Schwarzkopf, Denise

AU - Williams, Andrew E.

AU - Honda, Stacey

AU - Daida, Yihe

AU - Kushi, Lawrence H.

AU - Delate, Thomas

AU - Goddard, Katrina A.B.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - Membership of the CERGEN Study Team is provided in the Acknowledgments. The Comparative Effectiveness Research in Genomics of Colon Cancer (CERGEN) Study Team includes: Gwen Alexander, Henry Ford Health System (HFHS); Chris Anderson, Health Partners Institute for Education and Research (HPIER); Ajay Behl, HPIER; Kris Bennett, Kaiser Permanente Northwest (KPNW); Kathleen Bow, Kaiser Permanente Hawai'i (KPHI); Jennifer Carney, KPHI; Ned Colange, Denver Public Health of Colorado; Christopher Cold, Marshfield Clinic Research Foundation (MCRF); Deanna Cross, MCRF; YeeHwa Daida, KPHI; Padmavati Dandamudi, KPNW; Robert Davis, KPG; Teri Defor, HPIER; Thomas Delate, Kaiser Permanente Colorado (KPCO); Jessica Engel, MCRF; Rene Faryniarz, HFHS; Heather Spencer Feigelson, KPCO (lead author); Thomas Flottemesch, HPIER; Mamie Ford, KPNC; Jared Freml, KPCO; Kellyan Funk, KPCO; Joan Garhy, HFHS; Katrina Goddard, KPNW; Julie Harris, Kaiser Permanente Northern California (KPNC); Mia Hemmes, Kaiser Permanente Georgia (KPG); Paul Hitz, MCRF; Rebecca Holmes, KPNW; Stacey Honda, KPHI; Stephen Houston, KPNW; Karl Huang, KPNC; Clara Hwang, HFHS; Sheng-Fang Jiang, KPNC; Monique Johnson, Oregon Health and Sciences University (OHSU); Tia Kauffman, KPNW; Terrie Kitchner, MCRF; Richard Krajenta HFHS; Tatjana Kolevska, KPNC; Lawrence Kushi, KPNC; Smyth Lai, KPNW; Anh Q Le, KPCO; Loic LeMarchand, University of Hawaii; Petra Liljestrand, KPNC;Jennifer Lin KPNW; Celeste Machen, KPNW; Michael Maciosek, HPIER; Catherine McCarty, MCRF; Jennifer McCance, KPCO; Richard Meenan, KPNW; Alex Menter, KPCO; Jill Mesa,KPNW; Paul Meier, HFHS; Anousheh Mirabedi, KPNC; Judith Morse, KPNC; Kristin Muessig,KPNW; Andrew Nelson, HPIER; Carsie Nyirenda, KPCO; Maureen O'Keeffe Rosetti, KPNW; Kim Olson, KPNW; Suzanne O'Neill, Georgetown University; Adedayo Onitilo, MCRF; Brian Owens, HPIER;Pamala Pawloski, HPIER; Alanna Rahm, KPCO; C. Sue Richards, OHSU; Denise Schwarzkopf, KPNW; Caitlin Senger, KPNW; Carol Somkin KPNC; Amy Stone-Murai, KPHI;Nagendra Tirumali, KPNW; Laurie VanArman, HPIER; David Veenstra, University of Washington; Aleli Vinoya, KPHI; Carmel Wax, KPNW; Elizabeth Webber, KPNW; Jennifer Webster, KPNW; Evelyn Whitlock KPNW; Andrew Williams, KPHI; Carmen Wong, KPHI; Chan Zeng, KPCO; Sarah Zuber, KPNW. Purpose: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. Patients and Methods: We included 1186 metastatic CRC cases from seven health plans. A cutpoint of July, 2008, was used to define two KRAS testing time period groups: "pre-testing" (n = 760 cases) and ''post-testing'' (n = 426 cases). Overall survival (OS) was estimated, and the difference in median OS between the groups was calculated. The lower bound of the one-sided 95% confidence interval (CI) for the difference in survival was used to test the null hypothesis of post-testing inferiority. Multivariable Cox regression models were constructed to adjust for covariates. Results: The median unadjusted OS was 15.4 months (95% CI: 14.0-17.5) and 12.8 months (95% CI: 10.0-15.2) in the pre-and post-testing groups, respectively. The OS difference was -2.6 months with one-sided 95% lower confidence bound of -5.13 months, which was less than the non-inferiority margin (-5.0 months, unadjusted p = 0.06), leading to a failure to reject inferiority of OS in the post-testing period. In contrast, in the adjusted analysis, OS non-inferiority was identified in the post-testing period (p = 0.001). Sensitivity analyses using cutpoints before and after July, 2008, also met the criteria for non-inferiority. Conclusion: Implementation of KRAS testing did not influence CRC OS. Our data support the use of KRAS testing to guide administration of EGFR inhibitors for treatment of metastatic CRC without diminished OS.

AB - Membership of the CERGEN Study Team is provided in the Acknowledgments. The Comparative Effectiveness Research in Genomics of Colon Cancer (CERGEN) Study Team includes: Gwen Alexander, Henry Ford Health System (HFHS); Chris Anderson, Health Partners Institute for Education and Research (HPIER); Ajay Behl, HPIER; Kris Bennett, Kaiser Permanente Northwest (KPNW); Kathleen Bow, Kaiser Permanente Hawai'i (KPHI); Jennifer Carney, KPHI; Ned Colange, Denver Public Health of Colorado; Christopher Cold, Marshfield Clinic Research Foundation (MCRF); Deanna Cross, MCRF; YeeHwa Daida, KPHI; Padmavati Dandamudi, KPNW; Robert Davis, KPG; Teri Defor, HPIER; Thomas Delate, Kaiser Permanente Colorado (KPCO); Jessica Engel, MCRF; Rene Faryniarz, HFHS; Heather Spencer Feigelson, KPCO (lead author); Thomas Flottemesch, HPIER; Mamie Ford, KPNC; Jared Freml, KPCO; Kellyan Funk, KPCO; Joan Garhy, HFHS; Katrina Goddard, KPNW; Julie Harris, Kaiser Permanente Northern California (KPNC); Mia Hemmes, Kaiser Permanente Georgia (KPG); Paul Hitz, MCRF; Rebecca Holmes, KPNW; Stacey Honda, KPHI; Stephen Houston, KPNW; Karl Huang, KPNC; Clara Hwang, HFHS; Sheng-Fang Jiang, KPNC; Monique Johnson, Oregon Health and Sciences University (OHSU); Tia Kauffman, KPNW; Terrie Kitchner, MCRF; Richard Krajenta HFHS; Tatjana Kolevska, KPNC; Lawrence Kushi, KPNC; Smyth Lai, KPNW; Anh Q Le, KPCO; Loic LeMarchand, University of Hawaii; Petra Liljestrand, KPNC;Jennifer Lin KPNW; Celeste Machen, KPNW; Michael Maciosek, HPIER; Catherine McCarty, MCRF; Jennifer McCance, KPCO; Richard Meenan, KPNW; Alex Menter, KPCO; Jill Mesa,KPNW; Paul Meier, HFHS; Anousheh Mirabedi, KPNC; Judith Morse, KPNC; Kristin Muessig,KPNW; Andrew Nelson, HPIER; Carsie Nyirenda, KPCO; Maureen O'Keeffe Rosetti, KPNW; Kim Olson, KPNW; Suzanne O'Neill, Georgetown University; Adedayo Onitilo, MCRF; Brian Owens, HPIER;Pamala Pawloski, HPIER; Alanna Rahm, KPCO; C. Sue Richards, OHSU; Denise Schwarzkopf, KPNW; Caitlin Senger, KPNW; Carol Somkin KPNC; Amy Stone-Murai, KPHI;Nagendra Tirumali, KPNW; Laurie VanArman, HPIER; David Veenstra, University of Washington; Aleli Vinoya, KPHI; Carmel Wax, KPNW; Elizabeth Webber, KPNW; Jennifer Webster, KPNW; Evelyn Whitlock KPNW; Andrew Williams, KPHI; Carmen Wong, KPHI; Chan Zeng, KPCO; Sarah Zuber, KPNW. Purpose: Epidermal growth factor receptor (EGFR) inhibitors are approved for treating metastatic colorectal cancer (CRC); KRAS mutation testing is recommended prior to treatment. We conducted a non-inferiority analysis to examine whether KRAS testing has impacted survival in CRC patients. Patients and Methods: We included 1186 metastatic CRC cases from seven health plans. A cutpoint of July, 2008, was used to define two KRAS testing time period groups: "pre-testing" (n = 760 cases) and ''post-testing'' (n = 426 cases). Overall survival (OS) was estimated, and the difference in median OS between the groups was calculated. The lower bound of the one-sided 95% confidence interval (CI) for the difference in survival was used to test the null hypothesis of post-testing inferiority. Multivariable Cox regression models were constructed to adjust for covariates. Results: The median unadjusted OS was 15.4 months (95% CI: 14.0-17.5) and 12.8 months (95% CI: 10.0-15.2) in the pre-and post-testing groups, respectively. The OS difference was -2.6 months with one-sided 95% lower confidence bound of -5.13 months, which was less than the non-inferiority margin (-5.0 months, unadjusted p = 0.06), leading to a failure to reject inferiority of OS in the post-testing period. In contrast, in the adjusted analysis, OS non-inferiority was identified in the post-testing period (p = 0.001). Sensitivity analyses using cutpoints before and after July, 2008, also met the criteria for non-inferiority. Conclusion: Implementation of KRAS testing did not influence CRC OS. Our data support the use of KRAS testing to guide administration of EGFR inhibitors for treatment of metastatic CRC without diminished OS.

UR - http://www.scopus.com/inward/record.url?scp=84900455444&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900455444&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0094977

DO - 10.1371/journal.pone.0094977

M3 - Article

VL - 9

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e94977

ER -